CN1056068C - Red sage root use for antivirus of AIDS and hepatitis B - Google Patents
Red sage root use for antivirus of AIDS and hepatitis B Download PDFInfo
- Publication number
- CN1056068C CN1056068C CN95105902A CN95105902A CN1056068C CN 1056068 C CN1056068 C CN 1056068C CN 95105902 A CN95105902 A CN 95105902A CN 95105902 A CN95105902 A CN 95105902A CN 1056068 C CN1056068 C CN 1056068C
- Authority
- CN
- China
- Prior art keywords
- medicinal residues
- extract
- colourless
- minutes
- salviae miltiorrhizae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention proves that red sage root and Yunnan red sage root have the function of resisting AIDS, hepatitis B viruses and leukemia viruses, and discloses the application of the red sage root and the Yunnan red sage root to the preparation of antiviral drugs.
Description
The application is about the invention of Chinese herbal medicine Salvia miltiorrhiza Bge and Radix Salviae Miltiorrhizae novel medical use, belongs to the medicinal usage invention field.
Radix Salviae Miltiorrhizae (Salvia miltiorrhiza Bge) is the root of labiate, belongs to traditional activating blood and removing stasis drug.Modern pharmacological research thinks that it has multiple pharmacological effect (referring to " Chinese Medical Journal " 1978; 3:180, Jinhui's inscription, the research of the clinical application of red sage formulation and blood circulation promoting and blood stasis dispelling principle thereof).Plant studies show that, known composition has 20 kinds more than at least (referring to, Luo Houwei, drug for invigorating blood circulation and eliminating stasis---Radix Salviae Miltiorrhizae is progress of research at home, Chinese patent medicine research 1978 in the Radix Salviae Miltiorrhizae; And Zhang Decheng, etc. the structure of, research II.D (+) β of salvia-soluble active ingredient (3,4---dihydroxy phenyl) lactic acid, the Shanghai first medical college journal 1980; 5:384).Be used for the treatment of the existing many reports of chronic hepatitis about Radix Salviae Miltiorrhizae, be used for the preparation that mostly is water-soluble portion greatly of hepatopathy research at present, as Radix Salviae Miltiorrhizae decoct, Radix Salviae Miltiorrhizae Injection, FUFANG DANSHEN ZHUSHEYE and danshensu etc.Clinical research for Radix Salviae Miltiorrhizae shows that red sage formulation mainly shows as the effect of chronic hepatitis: recover liver function 1.; Retraction liver spleen, improve stasis of blood disease; 3. anti-hepatic fibrosis.Experimentation for the Treated with Radix Salviae Miltiorrhizae chronic hepatitis shows as: Radix Salviae Miltiorrhizae has the enzyme of falling liver protection effect, can promote liver cell regeneration, improves the liver blood flow supply, suppresses fibroplasia, prevents that experimental cirrhosis from taking place.And Radix Salviae Miltiorrhizae can also make established fiber dissipate, absorb except that the fibroplasia of inhibition effect is arranged.More than experiment or clinical data explanation red sage formulation has reliable medical function really for the treatment chronic hepatitis; but these researchs and use just relied on Radix Salviae Miltiorrhizae for human liver's protection, repair and prevent the effect of PD, nobody proposes also to confirm that Radix Salviae Miltiorrhizae has the effect of anti-hepatitis B virus up to now.And point out in the prior art when utilization Treated with Radix Salviae Miltiorrhizae chronic hepatitis, also to need to cooperate hepatitis virus resisting medicine (referring to Wang Zhenling, the clinical practice of Treated with Radix Salviae Miltiorrhizae chronic hepatitis and current state of experimental research, 1985 the 5th the 8th phases of volume of combination of Chinese and Western medicine magazine).Therefore, the treatment chronic hepatitis not only needs hepatoprotective, the more important thing is and wants eliminating pathogen, tackles the problem at its root, and the Chinese medicine of seeking a kind of energy anti-hepatitis B virus is the urgent needs of present medical circle.
Acquired immune deficiency syndrome (AIDS) is a kind of serious threat human health and the infectious disease of not having the specific treatment medicine, acquired immune deficiency syndrome (AIDS) is since being found in June, 1981, the short more than ten years have become since the dawn of human civilization, propagate the viral infectious the rapidest, the most extensive, that social influence is maximum.So far, world's HIV sufferers sum surpasses 600,000, and HIV the infected is estimated as 1,400 ten thousand.Meanwhile, more and more deep to the research of acquired immune deficiency syndrome (AIDS), active drug is also increasing, but however, aspect prevention and treatment, all achieving no breakthrough property progress had not both had the epidemic disease mattress, can not cure.Acquired immune deficiency syndrome (AIDS) is a kind of infectious disease that is caused by HIV (human immunodeficiency virus) (Human Immunodeficiency Virus) (HIV), and the medicine of seeking a kind of energy AIDS virus resisting is the world medicine worker target of effort for it.Although many medical workers have screened many to the effective medicine of acquired immune deficiency syndrome (AIDS), still there is not report about Radix Salviae Miltiorrhizae and Salvia miltiorrhiza Bge energy AIDS virus resisting in Chinese medicine.
The object of the invention is to confirm that Radix Salviae Miltiorrhizae has the effect of AIDS virus resisting and anti-hepatitis B virus.
The present invention also aims to medicine with Salvia miltiorrhiza Bge and Radix Salviae Miltiorrhizae exploitation becoming anti-AIDS and hepatitis B virus.
The said Salvia miltiorrhiza Bge of the present invention (Salvia Yunanensis C.H.wright), the another name Radix Salviae Miltiorrhizae, little RADIX SALVIAE MILTIORRHIZAE, Radix Rubiae Yunnanensis is the Labiatae perennial plant.P.321 this product is written into Yunnan drug standard in 1974, and Yunnan Province markets one's own products.Root is less, is the spindle shape, surperficial dark violet redness, frangibility, section out-of-flatness, wooden part sundown, feeble QI, sweet in the mouth, little bitterness.Be born in the patana of height above sea level 1800-2100 rice.Derive from the east, Yunnan.Microscopic features: the cross section of root is observed, and outermost is a phellem layer, aubergine, about 10 ordered series of numbers cells; The phloem broadness accounts for 1/3 to 2/3 of root radius, has most stone cells and groups of fibers to be dispersed in the parenchyma; Xylem is in central authorities, and wood strand 6-7 is individual, is radial arrangement, and wood strand is made up of the conduit and the wood fiber.
Radix Salviae Miltiorrhizae (Salvia Miltirrhiza Bunge) belongs to together with Salvia miltiorrhiza Bge, is distributed in all parts of the country.
The anti-AIDS of Radix Salviae Miltiorrhizae and the pharmacological action of hepatitis B virus mainly show by contained active ingredient in the Radix Salviae Miltiorrhizae, according to formulation method conventional in the prior art, Radix Salviae Miltiorrhizae can be made various pharmaceutical dosage form.
The present invention's experiment for convenience needs, and two kinds of effective ingredient of extraction Radix Salviae Miltiorrhizae (D1, E1), to confirm the effect of Radix Salviae Miltiorrhizae anti-AIDS and hepatitis B virus.
The preparation method of Radix Salviae Miltiorrhizae extract and technology:
(1) effective component in red sage (D1, E1) extract flow process:
Get a certain amount of Radix Salviae Miltiorrhizae, be crushed to a certain degree, go up in apparatus,Soxhlet's:
1. the chloroform reflux, extract, is extremely colourless.
2. medicinal residues reuse dehydrated alcohol extraction is extremely colourless.
3. the medicinal residues airing is to there being ethanol flavor, with 3 times of no saline water extraction of amount 3 times, at every turn
Soaked 30 minutes, and filtered, the filtrate lyophilizing gets components D 1.
4. extract the back medicinal residues, the no saline boiling of 3 times of amounts of reuse is extracted 3 times, and is each
30 fens kinds are filtered, and the filtrate lyophilizing gets composition E1.
(2) after the cold water soak,,, get D2 after cold the doing through ethanol elution by resin column.
(3) behind the water boil,,, get E2 after cold the doing through ethanol elution by resin column.
The present invention has carried out a large amount of experiments, has confirmed the pharmacological action of the anti-AIDS and the hepatitis B virus of Radix Salviae Miltiorrhizae and Salvia miltiorrhiza Bge.Following experimental example has illustrated the medical application of Radix Salviae Miltiorrhizae and Salvia miltiorrhiza Bge in further detail.
Experimental example 1 anti-hiv activity in cell culture: (1). in the cell culture of HIV (human immunodeficiency virus) 1 type AZT sensitivity or persister infected person, the antigenic inhibitory action cell virus of P24 D1 cold water is soaked E1 and boil
IC50 TC50 TI IC50 TC50 TI
μg/ml μg/ml μg/ml μg/ml
PBMC 018a, AZT (S) 12.7 964.3 77.5 2.24 61.3 27.37 human peripheral 018c, AZT (R) 7.3＞1,333 182.6 2.6＞1,333 512.7 mononuclear cell III B 11.3＞1,333 117.96 4.4＞1,333 303.0
H9 III B 28.7 2000＞84.64 9.07 500＞55.45 human T lymphocyte ± 14.1 ± 47.49 ± 0.83 ± 4.91
H9 MN 7 44.2
C8166 III B 0° 14.5 ＞1000 ＞68.97 2.2 ＞250 ＞113.64
Cell virus DR1 cold water soaks DR2 and boils
IC50 TC50 TI IC50 TC50 TI
μg/ml μg/ml μg/ml μg/ml
DR6 cold water DR3 boiling water
C8166 III B 6.4 250 39.06 1.5 250 166.67
DR8 DR2
18.9 ＞1000 ＞52.91 12.3 250 108.7
DR10 DR4
20.4＞1,000 49.02 2.0 250 125.0 (2). the stability of sample anti-hiv activity
The 5--9 month in 1994, extract 9 crowdes of D1,3 crowdes of E1, after room temperature was placed half a year, measured active in November, 1994, and except that the D1-8 poor effect, all the other 11 kinds are all effective.D1-3,4,5 effects are better.See Fig. 2.
The different samples of DR of in December, 1994 employing column chromatography method extraction and D1-3 and E1-2 measured simultaneously January nineteen ninety-five, and it is similar to tire.(3) .D1, E1 and AZT in the human peripheral blood cell cultivates to the synergism of AZT persister
D1 and E1 and AZT have synergism, see the following form: drug cell virus IC50 (μ g/ml)
D1 AZT E1 D1 PBMC 018c， 42.28
AZT resistance AZT 0.12D1+AZT 3.3 0.053FIC 0.52 ↑ 12.81 times ↑ 2.26 have 0.54 ↑ 17.94 times ↑ 74.35 times of synergy E1＞20AZT 0.033E1+AZT 0.017 0.27FIC that synergy experimental example 2 is arranged
The effect that D1 infects murine leukemia virus in the mice body
50 of Balb/c mices, 10 normal mice contrasts, all the other 40 lumbar injection murine leukemia virus RVB strain infected mice spleen 10% suspension 0.3ml/ are only, divide 4 groups, 10 every group, weigh, oral D1 0.5,1 of difference and 2g/kg after 2 hours, the matched group oral normal saline, is weighed at 20 days every days 2 times, killing Mus gets spleen and weighs, calculate spleen index, get anticoagulation, survey leukocyte (WBC), erythrocyte (RBC) number and hematochrome % (Hb%).With compare, calculate to suppress % and statistics t value and p value.
The effect that result: D1 infects murine leukemia virus RVB in the mice body
The group observation index
Mus is counted the heavy spleen index WBC of body weight spleen RBC Hb%
RVB virus 10 20.7 1.42 0.069 26,830 407.9 9.78
±1.34 ±0.34 ±0.017 ±9926.07 ±62.08 ±1.09
D1 10 21.2 0.85** 0.04** 14070** 586.7** 12.72**
2g/kg ±1.23 ±0.18 ±0.008 ±4455.2 ±76.36 ±0.93
Bid * 20 change % 2.42%-41.86%**-47.56%** 43.83%** 30.06%**
D1 10 20.7 0.88** 0.043** 13830** 547.8** 12.16**
1g/kg ±1.42 ±0.13 ±0.0075 ±4258.3 ±92.63 ±1.17
Bid * 20 change % 0-37.50%**-48.45%** 34.30%** 24.34%**
D1 10 20.7 1.48 0.071 21960 387.8 9.93
0.5g/kg ±1.42 ±0.31 ±0.014 ±7861.33 ±44.91 ±8.16
Bid * 20 changes % 0 3.20%-18.15%-4.93% 1.53%
Infected back 2 hours, oral 0.5,1.0 and 2.0g/kg, 1 day 2 times 20 days.1.0 spleen index and white blood cell count with 2.0g/kg group inhibition RVB viral infection Mus increase erythrocyte number and hematochrome %, compare with RVB viral infection matched group, and the meaning of highly significant is arranged.0.5g/kg it is invalid to organize.Repeated experiments, unanimity as a result.See Fig. 3.
E1 does not carry out the interior experiment to murine leukemia virus RVB infection effect of mice body because of the dose deficiency.Experimental example 3
The effect that D1 infects simian acquired immunodeficiency syndrome virus (SIV) in the monkey body
Rhesus Macacus 5-7kg, 8, male, health check-up does not have lymphadenectasis, simian acquired immunodeficiency syndrome antiviral antibody feminine gender before the experiment.D1,1-6 batch sample brown ceramic powder, the 5-7 month in 1994 prepared, and cell culture detects has inhibitory action to HIV-1 III B P24 antigen, with 0.5% methylcellulose obtain solution.8 monkeys are used U.S. SIVmac virus liquid 20-200MID50/ml intravenous injection, and 4 monkeys are irritated stomach to D1 and feed 100,300mg/kg, each 2, infecting the previous day and administration on the same day, 8 weeks once a day, oral 0.5% methylcellulose of virus control group once a day, is irritated 8 weeks of stomach, before the administration, administration the 10th, 14,17,21 and 30 days, and after the drug withdrawal 6 days (treating the 62nd day) and 36 days (treating the 44th day), get blood, separated plasma is measured virus in the HuT78 cell culture.The result: 1. plasma viral is dynamic:
Treatment group and the matched group monkey plasma viral average virus titer of number positive serum (TCID50/ml)
Group infects the average virus titer of plasma viral number positive/serum
Monkey several 10 days 14 days 17 days 21 days 30 days 62 days 90 days
D1 1/4 1/6.2 1/31.2 0/0 0/0 1/12.5 0/0 0/0
Infect contrast 3/4 0/0 2/12.5 3/192.5 1/43.7 1/12.5 1/12.5 0/0
The oral D18 of 4 SIV infected monkeys week viral infection rate and plasma viral titre infect the contrast monkeys relatively with 4, and infection rate reduces, and the plasma viral titre is low, the persistent period weak point.
2. lymph node pathological change: D1 treatment group alleviates than infecting matched group.
E1 does not carry out the interior test to the SIV infection effect of monkey body because of the dose deficiency.Experimental example 4
D1 and E1 are to the effect of hepatitis B virus
1.D1 and the toxicity of E1 in 2215 cells: D1 is 3962.78 μ g/ml to the median toxic concentration (TC50) of 2215 cell culture, E1 is 672 μ g/ml.Medication medication concentration and cytotoxic T C50 (μ g/ml)
5,000 2,500 1,250 625 312.5 156.25D1 cells 2 1------3962.78 pathological changes 3 (58.33%) 1 (25%)--
2 1 - -
2,000 1,000 500 250 125 62.5EI cells 43 2---pathological changes 4 (100%) 3 (75%) 1 (33.33%)-0-0-0 672
43 1---2.D1 and E1 be in 2215 cell culture
Expression has inhibitory action medium effective concentration 1148,1154 μ g/ml to HBeAg; Therapeutic index is respectively 3.45 and 3.44.
HBaAg is expressed D1 2000 μ g/ml, E1 500 μ g/ml maximum tolerated concentration unrestraint effects.
D1 and E1 in 2215 cell culture to the effect of HBV
3. at the intravital therapeutic effect of duck hepatitis B virus infection duck
| Experiment drug dose toxicity batch mg/ml TC50 CPE% | Effect | |
| HBeAg suppresses % IC50 TI | HBeAg suppresses % IC50 TI | |
| I D1 2000 1000 500 250 3962.78 E1 500 250 673 | 19.6＞2000＜1.98-2.57 invalid 14.4-47.93 27＞500＜1.35-33.41 is invalid | 53.8 1148 3.45 53.7 29.3 32.6 73.7 ＜250 ＞2.69 69.4 |
| II D1 2000 1000 500 250 3962.78 E1 500 250 125 62.5 673 | -2.81＞2000＜1-29.37 invalid-10.78-19.86-14.4＞500＜1-25.1-33.09-33.74 | 77.7 1154 3.44 41.6 36.8 22.0 80.3 204.9 3.29 53.6 44.4 -6.56 |
The clear 0.2ml/ of the 1 positive Sanguis Anas domestica of age in days Beijing duck vein infected duck hepatitis B virus (DHBV) only, oral D1 after 7 days, each 2g/kg of E1,1 day 2 times 10 days, virus control oral normal saline, every group of 5 ducks, got hematometry serum DHBV-DNA before the administration, after the administration after 5,10 days and the drug withdrawal in 3 days, the result is as seen: give oral D1 or E1 2g/kg, Bid * 20 and virus control group relatively, but highly significant suppresses the clear viral DNA of Sanguis Anas domestica.See figure
D1 and E1 treatment group and virus control group are counted suppression ratio (%) batch (only) T5 T10 P3I virus control group 6-54.19-6.77-53.94 to the comparative experiments group duck of DHBV-DNA suppression ratio in the duck body
D1 po，Bid×10
2 g/kg 6 64.15** 32.38 71.69*
E1 po，Bid×10
2 g/kg, 5 53.04** 74.71** 62.61II virus control 5-5.72 0.80-2.23
D1 po，Bid×10
2 g/kg 5 19.23 43.78** 13.24*
D1 po，Bid×10
4 g/kg 5 52.47** 62.61** 66.55
Identical with the virus control group respectively time D HBV-DNA suppression ratio of drug treatment group different time DHBV-DNA suppression ratio is (t check in groups) relatively, * P＜0.05, * * P＜0.01.Experimental example 5
The effect of D1 and E1 inducement interferon in the mice body.
Kunming mouse body weight 20g, ♂, 20 of every dosage groups, D1 oral 37.5,75 and 150mg/kg are once.E1 oral 75,150 and 300mg/kg are once.Coriolan (PSK) oral 250,500 and 2000mg/kg are once.Getting 5 in 2,6,18 and 24 hours respectively cuts open extremely and gets blood, separation of serum with culture fluid dilution back 2 times of dilutions in 1: 10, is handled with the cultivation of mice fibroblast L929 passage cell after 24 hours, culture fluid inclines, add vesicular stomatitis virus 48 hours, and established the contrast of viral infection and normal cell, when virus control is complete, observation sample cytopathy degree is pressed the Reed-Muench method, calculates sample half inhibition dilution factor and is the interferon relative potency.The results are shown in following table:
Serum interferon tire 26 18 24 hours D13 150mg/kg of u/ml drug dose route of administration oral 300---
75 234.4 - - -
37.5 141.25---E11 is 300 oral----
150 - - - -
75----PSK 1000 is oral 200---
500 100 - - -
250 100 - - -
150 - - - -
-0.1ml 1: 10 is invalid.
Experimental result shows: oral D1 37.5,75 of mice and 150mg/kg induce serum interferon respectively after one time 2 hours.141.25,234.4 and 300 relative potency u/ml, equal＜100u/ml after 6,18 and 24 hours.Oral E1 25,150 of mice and 300mg/kg once, 2,6,18,24 hours all＜100u/ml.Oral coriolan 150,250,500 of mice and 1000mg/kg are once, measure serum interferon relative potency 200,100,100u/ml after 2 hours respectively, illustrate that the oral D1 of mice induces serum interferon, is better than coriolan 37.5mg/kg and is equivalent to coriolan 250,500mg/kg approximately.The oral E1 300mg/kg of mice fails inducement interferon.Experimental example 6
D1 and E1 toxicity in vivo
The D1 oral toxicity is little, the mouse vein acute toxicity, and oral acute, subacute toxicity and oral subacute toxicity of duckling and the oral chronic toxicity of monkey, and the oral subacute toxicity of E1 duck sees Table.
Death observing time of drug toxicity zoopery number of animals dosage regimen
The anxious malicious Kunming mouse of D1 15 40g/kg po * 17 day 0/5
15 2g/kg iv * 17 day 0/5
25 40g/kg po * 17 day 0/5
25 2g/kg iv * 17 day 0/5
Inferior anxious poison 15 4g/kg po, Bid * 20 20 day 0/5
25 4g/kg po, Bid * 20 20 day 0/5
Inferior anxious malicious Beijing duck 15 2g/kg po, Bid * 10 13 day 0/5
25 4g/kg po, Bid * 10 13 day 0/5
Slow malicious Rhesus Macacus 12 100mg/kg qd * 56 March 0/2
300mg/kg qd * 56 March 0/2
The inferior anxious malicious Beijing duck 15 2g/kg po of E1, Bid * 10 13 day 0/5
Anxious malicious Kunming mouse 15 30g/kg po * 17 day 0/5
15 2g/kg iv * 17 day 5/5
15 1g/kg iv * 17 day 2/5
15 0.5g/kg iv * 17 day 1/5
D1 is little at mice, duckling and monkey toxicity in vivo.E1 has only carried out the experiment of duck toxicity in vivo because of the dose deficiency, and oral 2g/kg 1 day 2 times 10 days, does not see toxicity.Experimental example 7 Radix Salviae Miltiorrhizae extract Do and TANSHINONES 11-A and danshensu in people T-lymphocyte is cultivated to the inhibitory action of HIV (human immunodeficiency virus) (Human Immunodeficiency Virus).Sample: 1. Radix Salviae Miltiorrhizae extract Do: preparation method: decocting wine is heavy, cold doing.
2. tanshinone (Tanshinone IIA).
Danshensu (b-(3, the 4-dihydroxy phenyl) sodium lactate, Danshensu).Virus: HIV (human immunodeficiency virus) (Human Immunodeficiency Virus) (HTLV-IIIB) cell: (C8166, H9) viral index: cytopathy: giant cell forms (CPE) to people T-lymphocyte; P24 antigen (P24ng/ml) toxicity index: cytopathy (CPE), 3HTdR mixes (cpm) table: Radix Salviae Miltiorrhizae and danshensu and Tanshinone I I-A in people T-lymphocyte is cultivated to the inhibitory action medicine cell virus index IC50 TC50 TI of HIV (human immunodeficiency virus) (Human Immunodeficiency Virus)
Ug/ml ug/mlD0 C8166 HTLV-IIIB giant cell forms (CPE) 176.77 1000.0 5.66
3HTdR mixes (cpm) 343.2 1.94 TANSHINONES C8166 HTLV-IIIB giant cells and forms (CPE) 26.90 176.8 6.57
3HTdR mixes (cpm) 108.2 4.02 danshensu H9 HTLV-IIIB P24 (ng/ml) 30.4
3HTdR mixes (cpm) 348.0 11.45
Claims (5)
1. Salvia miltiorrhiza Bge effective site D
1And E
1Application in preparation AIDS virus resisting medicine, D wherein
1And E
1Be to extract through following method to obtain:
Get a certain amount of Radix Salviae Miltiorrhizae, be crushed to a certain degree, go up in apparatus,Soxhlet's, use the chloroform reflux, extract,, to colourless; Medicinal residues reuse dehydrated alcohol extraction is to colourless; The medicinal residues airing is to there being ethanol flavor, with 3 times of no saline water extraction of amount 3 times, soaked 30 minutes at every turn, and filtration, the filtrate lyophilizing must components D
1Medicinal residues after extracting, the no saline boiling of 3 times of amounts of reuse is extracted 3 times, and each 30 minutes, to filter, the filtrate lyophilizing gets composition E
1
2. according to the application of claim 1, it is characterized in that Salvia miltiorrhiza Bge effective site D
1And E
1Be used for preparation and synergistic AIDS virus resisting medicine arranged with AZT.
3. Salvia miltiorrhiza Bge effective site D
1And E
1Application in the medicine of preparation leukemia virus, D wherein
1And E
1Be to extract through following method to obtain:
Get a certain amount of Radix Salviae Miltiorrhizae, be crushed to a certain degree, go up in apparatus,Soxhlet's, use the chloroform reflux, extract,, to colourless; Medicinal residues reuse dehydrated alcohol extraction is to colourless; The medicinal residues airing is to there being ethanol flavor, with 3 times of no saline water extraction of amount 3 times, soaked 30 minutes at every turn, and filtration, the filtrate lyophilizing must components D
1Medicinal residues after extracting, the no saline boiling of 3 times of amounts of reuse is extracted 3 times, and each 30 minutes, to filter, the filtrate lyophilizing gets composition E
1
4. Salvia miltiorrhiza Bge effective site D
1And E
1Application in the medicine of preparation anti-hepatitis B virus, D wherein
1And E
1Be to extract through following method to obtain:
Get a certain amount of Radix Salviae Miltiorrhizae, be crushed to a certain degree, go up in apparatus,Soxhlet's, use the chloroform reflux, extract,, to colourless; Medicinal residues reuse dehydrated alcohol extraction is to colourless; The medicinal residues airing is to there being ethanol flavor, with 3 times of no saline water extraction of amount 3 times, soaked 30 minutes at every turn, and filtration, the filtrate lyophilizing must components D
1Medicinal residues after extracting, the no saline boiling of 3 times of amounts of reuse is extracted 3 times, and each 30 minutes, to filter, the filtrate lyophilizing gets composition E
1
5. Salvia miltiorrhiza Bge effective site D
1And E
1Application in preparing the medicine that can induce serum interferon, D wherein
1And E
1Be to extract through following method to obtain:
Get a certain amount of Radix Salviae Miltiorrhizae, be crushed to a certain degree, go up in apparatus,Soxhlet's, use the chloroform reflux, extract,, to colourless; Medicinal residues reuse dehydrated alcohol extraction is to colourless; The medicinal residues airing is to there being ethanol flavor, with 3 times of no saline water extraction of amount 3 times, soaked 30 minutes at every turn, and filtration, the filtrate lyophilizing must components D
1Medicinal residues after extracting, the no saline boiling of 3 times of amounts of reuse is extracted 3 times, and each 30 minutes, to filter, the filtrate lyophilizing gets composition E
1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95105902A CN1056068C (en) | 1995-05-29 | 1995-05-29 | Red sage root use for antivirus of AIDS and hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95105902A CN1056068C (en) | 1995-05-29 | 1995-05-29 | Red sage root use for antivirus of AIDS and hepatitis B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1136928A CN1136928A (en) | 1996-12-04 |
| CN1056068C true CN1056068C (en) | 2000-09-06 |
Family
ID=5075637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95105902A Expired - Fee Related CN1056068C (en) | 1995-05-29 | 1995-05-29 | Red sage root use for antivirus of AIDS and hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1056068C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457748C (en) * | 2006-10-18 | 2009-02-04 | 中国医学科学院医药生物技术研究所 | Novel phenolic acid compounds of tanshin polyphenolic acid N and application thereof |
| CN107582546A (en) * | 2016-07-08 | 2018-01-16 | 北京城市学院 | Sodium Danshensu improves the purposes of immunity medicine preparing |
-
1995
- 1995-05-29 CN CN95105902A patent/CN1056068C/en not_active Expired - Fee Related
Non-Patent Citations (6)
| Title |
|---|
| 《中国中药杂志》19(6) 1994.1.1 李庆华等，治疗病毒性肝炎的常用中药及选用 * |
| 《中西医结合杂志》11(8) 1991.1.1 吴伯平，国内外中医药防治艾滋病研究进展 * |
| 《中西医结合杂志》9(8) 1989.1.1 杨鉴英等，中药抗乙型肝炎病毒的实验研究 * |
| 《云南呀知学院学报》14(2) 1991.1.1 淤泽溥等，丹参保肝作用机理研究进展 * |
| 《实用中西医结合杂志》3(6) 1990.1.1 姜菊英等，丹参及其制剂的临床新用途 * |
| 《实用中西医结合杂志》3(6) 1990.1.1 姜菊英等，丹参及其制剂的临床新用途;《云南呀知学院学报》14(2) 1991.1.1 淤泽溥等，丹参保肝作用机理研究进展;《中国中药杂志》19(6) 1994.1.1 李庆华等，治疗病毒性肝炎的常用中药及选用;《中西医结合杂志》11(8) 1991.1.1 吴伯平，国内外中医药防治艾滋病研究进展;《中西医结合杂志》9(8) 1989.1.1 杨鉴英等，中药抗乙型肝炎病毒的实验研究 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1136928A (en) | 1996-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1065750C (en) | Medicine taken after being mixed with boiling water for liver trouble | |
| CN1056068C (en) | Red sage root use for antivirus of AIDS and hepatitis B | |
| CN1644213A (en) | Chinese medicinal preparation for treating liver cancer, hepatitis B cirrhosis and preventing liver fibrillation and preparation thereof | |
| CN1168488C (en) | Chinese medicinal preparation for treating pyretic stranguria | |
| CN101044857A (en) | Application of compounding preparation in medicine for treating human Aids hepatitis and skin diseases | |
| CN1087275A (en) | Treatment ischemic brain, cardiovascular preparation Shumaining | |
| CN1419455A (en) | Physiologically active compositions of basidiomycotina and araliaceae extracts | |
| CN1199684C (en) | Chinese medicine for treating hepatitis B and process for preparing same | |
| CN1051470C (en) | Medicine for curing viral hepatitis | |
| CN1059104C (en) | Capsule for anti hepatitis B | |
| CN100346800C (en) | Chinese medicine composition for preventing and treating hepatitis | |
| CN1814076A (en) | Chinese medicine composition new use | |
| CN1136939A (en) | Chinese drugs for curing hepatitis B | |
| CN1216626C (en) | Shenhong capsule with actions of removing blood stasis and obstruction | |
| CN1927245A (en) | Application of Herba Solidaginis in preparing medicine for preventing and treating AIDS virus | |
| CN1190229C (en) | Medicine for curing hepatitis B | |
| CN1795901A (en) | Medication for removing toxic heat, eliminating wetness and treating jaundice | |
| CN1159057C (en) | Medicine for treating hepatitis, and preparing process thereof | |
| CN1857404A (en) | Medicine composition for treating viral hepatitis and its preparing method | |
| CN1965897A (en) | Chinese medicinal composition for resisting hepatic fibrosis and method for preparing same | |
| CN1304043C (en) | Longhedan pills and their preparation | |
| CN1733107A (en) | Medicine for treating coronary disease and apoplexy sequelae and process for preparing the same | |
| CN1824080A (en) | Medicinal composition for antivirus and its preparation method | |
| CN1586546A (en) | Medicine for treating liver and biliary diseases and its preparing method | |
| CN102552437B (en) | Chinese medicinal composition for treating acquired immune deficiency syndrome and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1041229 Country of ref document: HK |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20000906 |